Intanza

RSS

Withdrawn

This medicine's authorisation has been withdrawn

influenza vaccine (split virion, inactivated)
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 3 August 2018, the European Commission withdrew the marketing authorisation for Intanza (influenza vaccine (split virion, inactivated)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Pasteur Europe, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Intanza was granted marketing authorisation in the EU on 24 February 2009 for prophylaxis of influenza in individuals 60 years of age and over. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2013. There are other medicinal products similar to Intanza authorised and marketed in the EU. 

The European Public Assessment Report (EPAR) for Intanza is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (637.89 KB - PDF)

Skatīt

español (ES) (545.64 KB - PDF)

Skatīt

čeština (CS) (611.73 KB - PDF)

Skatīt

dansk (DA) (545.52 KB - PDF)

Skatīt

Deutsch (DE) (547.47 KB - PDF)

Skatīt

eesti (ET) (552.93 KB - PDF)

Skatīt

ελληνικά (EL) (635.18 KB - PDF)

Skatīt

français (FR) (547.7 KB - PDF)

Skatīt

hrvatski (HR) (567.46 KB - PDF)

Skatīt

italiano (IT) (544.82 KB - PDF)

Skatīt

latviešu (LV) (610.29 KB - PDF)

Skatīt

lietuvių (LT) (570.94 KB - PDF)

Skatīt

magyar (HU) (605.73 KB - PDF)

Skatīt

Malti (MT) (615.9 KB - PDF)

Skatīt

Nederlands (NL) (545.14 KB - PDF)

Skatīt

polski (PL) (608.34 KB - PDF)

Skatīt

português (PT) (545.74 KB - PDF)

Skatīt

română (RO) (571.27 KB - PDF)

Skatīt

slovenčina (SK) (613.61 KB - PDF)

Skatīt

slovenščina (SL) (601.13 KB - PDF)

Skatīt

suomi (FI) (544.59 KB - PDF)

Skatīt

svenska (SV) (545.64 KB - PDF)

Skatīt

Product information

български (BG) (1.47 MB - PDF)

Skatīt

español (ES) (1 MB - PDF)

Skatīt

čeština (CS) (1.31 MB - PDF)

Skatīt

dansk (DA) (974.04 KB - PDF)

Skatīt

Deutsch (DE) (1.01 MB - PDF)

Skatīt

eesti (ET) (965.77 KB - PDF)

Skatīt

ελληνικά (EL) (1.7 MB - PDF)

Skatīt

français (FR) (839.69 KB - PDF)

Skatīt

hrvatski (HR) (992.86 KB - PDF)

Skatīt

italiano (IT) (951.14 KB - PDF)

Skatīt

latviešu (LV) (1.25 MB - PDF)

Skatīt

lietuvių (LT) (891.45 KB - PDF)

Skatīt

magyar (HU) (1.44 MB - PDF)

Skatīt

Malti (MT) (1.5 MB - PDF)

Skatīt

Nederlands (NL) (980.56 KB - PDF)

Skatīt

polski (PL) (1.22 MB - PDF)

Skatīt

português (PT) (783.19 KB - PDF)

Skatīt

română (RO) (875.4 KB - PDF)

Skatīt

slovenčina (SK) (1.6 MB - PDF)

Skatīt

slovenščina (SL) (1.53 MB - PDF)

Skatīt

suomi (FI) (785.83 KB - PDF)

Skatīt

svenska (SV) (779.44 KB - PDF)

Skatīt

Íslenska (IS) (1.02 MB - PDF)

Skatīt

norsk (NO) (1004.45 KB - PDF)

Skatīt
Latest procedure affecting product information:II/0054
07/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (566.72 KB - PDF)

Skatīt

español (ES) (540.21 KB - PDF)

Skatīt

čeština (CS) (546.42 KB - PDF)

Skatīt

dansk (DA) (539.59 KB - PDF)

Skatīt

Deutsch (DE) (531.18 KB - PDF)

Skatīt

eesti (ET) (539.24 KB - PDF)

Skatīt

ελληνικά (EL) (567.85 KB - PDF)

Skatīt

français (FR) (506.88 KB - PDF)

Skatīt

hrvatski (HR) (543.3 KB - PDF)

Skatīt

italiano (IT) (540.42 KB - PDF)

Skatīt

latviešu (LV) (557.31 KB - PDF)

Skatīt

lietuvių (LT) (524.28 KB - PDF)

Skatīt

magyar (HU) (556.81 KB - PDF)

Skatīt

Malti (MT) (549.14 KB - PDF)

Skatīt

Nederlands (NL) (531.06 KB - PDF)

Skatīt

polski (PL) (548.37 KB - PDF)

Skatīt

português (PT) (530.41 KB - PDF)

Skatīt

română (RO) (532.7 KB - PDF)

Skatīt

slovenčina (SK) (548.64 KB - PDF)

Skatīt

slovenščina (SL) (544.53 KB - PDF)

Skatīt

suomi (FI) (538.06 KB - PDF)

Skatīt

svenska (SV) (529.92 KB - PDF)

Skatīt

Íslenska (IS) (540.06 KB - PDF)

Skatīt

norsk (NO) (530.41 KB - PDF)

Skatīt

Product details

Name of medicine
Intanza
Active substance
influenza virus (inactivated, split) of the following strains:A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)
International non-proprietary name (INN) or common name
influenza vaccine (split virion, inactivated)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BB02

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.
The use of Intanza should be based on official recommendations.

Authorisation details

EMA product number
EMEA/H/C/000957
Marketing authorisation holder
Sanofi Pasteur Europe

2 Avenue Pont Pasteur
69007 Lyon
France

Marketing authorisation issued
24/02/2009
Withdrawal of marketing authorisation
03/08/2018
Revision
18

Assessment history

This page was last updated on

Share this page